UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

(Amendment No.                 )

Filed by the Registrant   ☒

Filed by a Party other than the Registrant   ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

ACORDA THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

EXTREMELY IMPORTANT

Re: ACORDA THERAPEUTICS, INC. — POTENTIAL DELISTING

Dear Stockholder:

Please contact us as soon as possible. We have attempted to reach you on a very important matter related to your investment in ACORDA THERAPEUTICS, INC. Please call us at 1-800-967-5051 (or +1-212-269-5550 for international calls). Our hours of operation are 9:00 a.m. and 10:00 p.m. Eastern time Monday through Friday or between 10:00 a.m. and 6:00 p.m. Eastern time on Saturdays.

Thank you.

Sincerely,

Ron Cohen, M.D.

President and Chief Executive Officer

ACORDA THERAPEUTICS, INC.